194 related articles for article (PubMed ID: 19666091)
1. Exploration of endocrine-disrupting chemicals on estrogen receptor alpha by the agonist/antagonist differential-docking screening (AADS) method: 4-(1-adamantyl)phenol as a potent endocrine disruptor candidate.
Nose T; Tokunaga T; Shimohigashi Y
Toxicol Lett; 2009 Dec; 191(1):33-9. PubMed ID: 19666091
[TBL] [Abstract][Full Text] [Related]
2. Competitive molecular docking approach for predicting estrogen receptor subtype α agonists and antagonists.
Ng HW; Zhang W; Shu M; Luo H; Ge W; Perkins R; Tong W; Hong H
BMC Bioinformatics; 2014; 15 Suppl 11(Suppl 11):S4. PubMed ID: 25349983
[TBL] [Abstract][Full Text] [Related]
3. Identification of putative estrogen receptor-mediated endocrine disrupting chemicals using QSAR- and structure-based virtual screening approaches.
Zhang L; Sedykh A; Tripathi A; Zhu H; Afantitis A; Mouchlis VD; Melagraki G; Rusyn I; Tropsha A
Toxicol Appl Pharmacol; 2013 Oct; 272(1):67-76. PubMed ID: 23707773
[TBL] [Abstract][Full Text] [Related]
4. Estrogenicity of halogenated bisphenol A: in vitro and in silico investigations.
Zhang J; Li T; Wang T; Yuan C; Zhong S; Guan T; Li Z; Wang Y; Yu H; Luo Q; Wang Y; Zhang T
Arch Toxicol; 2018 Mar; 92(3):1215-1223. PubMed ID: 29152682
[TBL] [Abstract][Full Text] [Related]
5. Exploring interactions of endocrine-disrupting compounds with different conformations of the human estrogen receptor alpha ligand binding domain: a molecular docking study.
Celik L; Davey J; Lund D; Schiøtt B
Chem Res Toxicol; 2008 Nov; 21(11):2195-206. PubMed ID: 18921983
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity.
Greschik H; Flaig R; Renaud JP; Moras D
J Biol Chem; 2004 Aug; 279(32):33639-46. PubMed ID: 15161930
[TBL] [Abstract][Full Text] [Related]
7. In silico identification and pharmacological evaluation of novel endocrine disrupting chemicals that act via the ligand-binding domain of the estrogen receptor α.
McRobb FM; Kufareva I; Abagyan R
Toxicol Sci; 2014 Sep; 141(1):188-97. PubMed ID: 24928891
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor alpha.
Dayan G; Lupien M; Auger A; Anghel SI; Rocha W; Croisetière S; Katzenellenbogen JA; Mader S
Mol Pharmacol; 2006 Aug; 70(2):579-88. PubMed ID: 16679488
[TBL] [Abstract][Full Text] [Related]
9. Structural insights into Resveratrol's antagonist and partial agonist actions on estrogen receptor alpha.
Chakraborty S; Levenson AS; Biswas PK
BMC Struct Biol; 2013 Oct; 13():27. PubMed ID: 24160181
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha.
Chakraborty S; Biswas PK
J Mol Model; 2014 Aug; 20(8):2338. PubMed ID: 25060147
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor-ligand complexes measured by chip-based nanoelectrospray mass spectrometry: an approach for the screening of endocrine disruptors.
Bovet C; Wortmann A; Eiler S; Granger F; Ruff M; Gerrits B; Moras D; Zenobi R
Protein Sci; 2007 May; 16(5):938-46. PubMed ID: 17400923
[TBL] [Abstract][Full Text] [Related]
12. Interactions of bisphenol diglycidyl ethers with estrogen receptors α: Fluorescence polarization, reporter gene, and molecular modeling investigations.
Zhang J; Lv C; Li Z; Guan T; Wang Y; Li T; Zhang T
Toxicol Lett; 2020 Oct; 332():14-19. PubMed ID: 32619634
[TBL] [Abstract][Full Text] [Related]
13. Some nonylphenol isomers show antiestrogenic potency in the MVLN cell assay.
Preuss TG; Gurer-Orhan H; Meerman J; Ratte HT
Toxicol In Vitro; 2010 Feb; 24(1):129-34. PubMed ID: 19720131
[TBL] [Abstract][Full Text] [Related]
14. Exploring the binding features of polybrominated diphenyl ethers as estrogen receptor antagonists: docking studies.
Yang WH; Wang ZY; Liu HL; Yu HX
SAR QSAR Environ Res; 2010 Apr; 21(3-4):351-67. PubMed ID: 20544555
[TBL] [Abstract][Full Text] [Related]
15. Determination and analysis of agonist and antagonist potential of naturally occurring flavonoids for estrogen receptor (ERα) by various parameters and molecular modelling approach.
Puranik NV; Srivastava P; Bhatt G; John Mary DJS; Limaye AM; Sivaraman J
Sci Rep; 2019 May; 9(1):7450. PubMed ID: 31092862
[TBL] [Abstract][Full Text] [Related]
16. Charge clamps of lysines and hydrogen bonds play key roles in the mechanism to fix helix 12 in the agonist and antagonist positions of estrogen receptor α: intramolecular interactions studied by the ab initio fragment molecular orbital method.
Watanabe C; Fukuzawa K; Tanaka S; Aida-Hyugaji S
J Phys Chem B; 2014 May; 118(19):4993-5008. PubMed ID: 24725156
[TBL] [Abstract][Full Text] [Related]
17. ERα-agonist and ERβ-antagonist bifunctional next-generation bisphenols with no halogens: BPAP, BPB, and BPZ.
Liu X; Matsuyama Y; Shimohigashi M; Shimohigashi Y
Toxicol Lett; 2021 Jul; 345():24-33. PubMed ID: 33857583
[TBL] [Abstract][Full Text] [Related]
18. Elucidation of Agonist and Antagonist Dynamic Binding Patterns in ER-α by Integration of Molecular Docking, Molecular Dynamics Simulations and Quantum Mechanical Calculations.
Sakkiah S; Selvaraj C; Guo W; Liu J; Ge W; Patterson TA; Hong H
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502280
[TBL] [Abstract][Full Text] [Related]
19. Monitoring ligand modulation of protein-protein interactions by mass spectrometry: estrogen receptor alpha-SRC1.
Bovet C; Ruff M; Eiler S; Granger F; Wenzel R; Nazabal A; Moras D; Zenobi R
Anal Chem; 2008 Oct; 80(20):7833-9. PubMed ID: 18778086
[TBL] [Abstract][Full Text] [Related]
20. Preliminary molecular dynamic simulations of the estrogen receptor alpha ligand binding domain from antagonist to apo.
McGee TD; Edwards J; Roitberg AE
Int J Environ Res Public Health; 2008 Jun; 5(2):111-4. PubMed ID: 18678925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
